Cross-reactive antibody and functional T-cell responses to Bundibugyo virus induced by Zaire ebolavirus vaccination and infection

EBOV vaccination and infection elicit BDBV-cross-reactive T-cell responses, with the strongest BDBV-reactive CD8 magnitude in EVD survivors at 24.7% [20.3–33.1].

• Why it matters: No licensed BDBV-specific vaccine exists for the current outbreak in the Democratic Republic of the Congo, and it is unclear whether EBOV vaccination or infection provides cross-protection.
• What they did: CD4 and CD8 responses were measured after 8-day peptide-pool expansion (EBOV, BDBV, SUDV, MARV GP) and BDBV-binding antibodies were quantified by multiplex assay in vaccine recipients (Ad26.ZEBOV/MVA-BN-Filo, n=10; rVSVG-ZEBOV-GP, n=10 or n=8) and EVD survivors sampled ~3 years post-infection (n=10).
• The result: BDBV-binding antibodies were detected after both vaccine regimens, peaking in survivors at 491 [330–1261] net MFI, and EBOV- and BDBV-reactive cellular and humoral responses were positively correlated among vaccinees.

AI summary of the abstract · may contain errors · not medical advice · read the paper.